You are here
VISDEX CORP
UEI: N/A
# of Employees: 2
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Phase Contrast OCT for Non-Invasive Imaging of Retinovascular Disease
Amount: $800,526.00DESCRIPTION (provided by applicant): Since its introduction in the 1960's, fluorescein angiography (FA) has been the gold standard for retinal vascular diagnosis. However, FA is costly, invasive, ...
STTRPhase II2013Department of Health and Human Services National Institutes of Health -
Characterization of Exudative Macular Degeneration and Diabetic Retinopathy Using
Amount: $153,908.00DESCRIPTION (provided by applicant): Since its first use in the retina in 1961, fluorescein angiography (FA) has been the gold standard for objective characterization of retinovascular disease (e.g. d ...
STTRPhase I2010Department of Health and Human Services National Institutes of Health -
Novel Treatment for Post-LASIK Ectasia
Amount: $347,984.00DESCRIPTION (provided by applicant): Of the 1.4 million refractive surgeries performed each year using laser assisted in situ keratomileusis (LASIK) in the U.S., 1 in 2500 will result in post-LASIK ec ...
STTRPhase I2009Department of Health and Human Services National Institutes of Health -
Novel Treatment for Degenerative Myopia
Amount: $645,867.00DESCRIPTION (provided by applicant): Myopia affects 30% of the population in the U.S. and Europe, and 70-90% of the population in some Asian countries. High myopia of greater than 8 diopters affects ...
STTRPhase II2008Department of Health and Human Services National Institutes of Health -
Novel Treatment for Degenerative Myopia
Amount: $270,496.00DESCRIPTION (provided by applicant): Photopolymerization has provided a powerful tool for tissue engineering through localized synthesis of therapeutic materials in situ. To date, strategies to create ...
STTRPhase I2006Department of Health and Human Services National Institutes of Health -
Novel Treatment for Degenerative Myopia
Amount: $270,496.00DESCRIPTION (provided by applicant): Photopolymerization has provided a powerful tool for tissue engineering through localized synthesis of therapeutic materials in situ. To date, strategies to create ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health